Healthcare >> Analyst Interviews >> August 5, 2013
New Product Generation and an Easing Regulatory Environment in Biopharmaceuticals
Andrew Baum, M.D., joined Citigroup Investment & Research Analysis in September 2011 as the Global Head of Healthcare Research. Before joining the firm, Dr. Baum was at Morgan Stanley for 14 years where he was the top ranked European Pharmaceutical Analyst in the Extel Poll for six years. Dr. Baum and his team consistently ranked in the top three teams in external EU and global investor polls — Institutional Investor, Greenwich and Reuters. Before this, he was a U.K. Pharmaceutical and Biotechnology Analyst at Salomon Brothers. From 1994 to 1996, he was a practicing Physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford, the medical center of Oxford University, where he completed his residency. Dr. Baum holds an M.A. in physiological sciences and an M.D. from Oxford University. Profile
TWST: Looking back, the Big Pharma group has done pretty well relative to the market so far this year. Why?
Dr. Baum: Well, it's acombination of factors. I think the bulk of the